Regeneron Pharmaceuticals Inc. (REGN) Financial Statements (2026 and earlier)

Company Profile

Business Address 777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
State of Incorp. NY
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,6058,4447,4708,3499,0139,797
Cash and cash equivalent3,1182,5061,9963,0902,4882,012
Short-term investments5,4875,9375,4745,2596,5247,785
Restricted cash and investments672031 
Receivables5,7415,6875,6105,5616,2126,107
Inventory, net of allowances, customer advances and progress billings3,2013,2543,2063,1923,0873,018
Inventory3,2013,2543,2063,1923,0873,018
Other undisclosed current assets469589555466348412
Total current assets:18,02217,98116,86017,57218,66119,334
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 577   591 
Operating lease, right-of-use asset 246   217 
Long-term investments and receivables10,29510,28610,0589,2768,9008,491
Long-term investments10,29510,28610,0589,2768,9008,491
Intangible asset, including goodwill, after accumulated amortization1,2571,3811,3521,1671,1491,120
Intangible asset, excluding goodwill, after accumulated amortization1,2571,3811,3521,1671,1491,120
Deferred income tax assets4,0773,8473,5723,4433,3143,015
Other noncurrent assets1,8211,6731,5371,3931,1361,043
Other undisclosed noncurrent assets4,2645,0024,8414,6943,7914,439
Total noncurrent assets:22,53722,18921,36019,97419,09918,108
TOTAL ASSETS:40,55940,16938,21937,54537,75937,442
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,8769047247062,527497
Accounts payable939904724706790497
Accrued liabilities 1,644   1,425 
Other undisclosed accounts payable and accrued liabilities 294   312 
Deferred revenue553546482619628627
Debt      
Other undisclosed current liabilities9392,9762,4612,2427902,537
Total current liabilities:4,3684,4253,6673,5673,9443,661
Noncurrent Liabilities
Long-term debt and lease obligation2,7062,7062,7052,7052,7042,704
Long-term debt, excluding current maturities1,9861,9861,9851,9851,9841,984
Finance lease, liability 720720720720720720
Liabilities, other than long-term debt2,2282,0811,9081,8861,7571,751
Deferred revenue209219206212186207
Other liabilities2,0191,8621,7021,6741,5711,544
Total noncurrent liabilities:4,9334,7874,6134,5914,4624,455
Total liabilities:9,3029,2128,2808,1588,4068,116
Equity
Equity, attributable to parent, including:31,25730,95829,93929,38829,35429,326
Treasury stock, value(18,613)(17,944)(17,285)(16,218)(15,167)(14,192)
Additional paid in capital13,99513,78713,49113,19212,85612,703
Accumulated other comprehensive income (loss)78695329(8)60
Retained earnings35,79735,04633,68032,38431,67330,755
Other undisclosed equity, attributable to parent000000
Total equity:31,25730,95829,93929,38829,35429,326
TOTAL LIABILITIES AND EQUITY:40,55940,16938,21937,54537,75937,442

Income Statement (P&L) ($ in millions)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues3,8843,7543,6763,0293,7893,721
Cost of revenue(603)(595)(540)(477)(595)(555)
Gross profit:3,2813,1603,1352,5523,1953,165
Operating expenses(2,401)(2,133)(2,056)(1,960)(2,204)(1,986)
Other operating income (expense), net  10  (16)(8)
Other undisclosed operating income (loss)  (10)  168
Operating income:8801,0271,0805929901,180
Nonoperating income (expense)164737439313(32)314
Other nonoperating income (expense)176756443322(22)327
Interest and debt expense(12)(19)(4)(9)(11)(14)
Income from continuing operations before equity method investments, income taxes:1,0321,7441,5158969481,479
Other undisclosed income from continuing operations before income taxes1219491114
Income from continuing operations before income taxes:1,0441,7631,5199059581,493
Income tax expense(199)(303)(127)(96)(40)(152)
Net income available to common stockholders, diluted:8451,4601,3928099181,341

Comprehensive Income ($ in millions)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income:8451,4601,3928099181,341
Comprehensive income:8451,4601,3928099181,341
Other undisclosed comprehensive income (loss), net of tax, attributable to parent9172337(68)130
Comprehensive income, net of tax, attributable to parent:8531,4771,4158468501,471

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: